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Reduced accumulation of cisplatin is the most consistent feature seen in cisplatin-resistant (CP-r) cells that are cross-resistant to other
cytotoxic compounds, such as methotrexate. In this report, defective uptake of a broad range of compounds, including [
14C]-
carboplatin, [
3H]MTX, [
3H]folic acid (FA), [
125I]epidermal growth factor,
59Fe, [
3H]glucose, and [
3H]proline, as well as
73As
5þ and
73As
3þ, was detected in CP-r human hepatoma and epidermal carcinoma cells that we have previously shown are defective in fluid-
phase endocytosis. Downregulation of several small GTPases, such as rab5, rac1, and rhoA, which regulate endocytosis, was found in
CP-r cells. However, expression of an early endosomal protein and clathrin heavy chain was not changed, suggesting that the
defective endocytic pathway is clathrin independent. Reduced expression of the cell surface protein, folate-binding protein (FBP),
which is a carrier for the uptake of MTX, was also observed in the CP-r cells by confocal immunofluorescence microscopy and Real-
Time PCR. Reactivation of the silenced FBP gene in the CP-r cells by a DNA demethylation agent, 2-deoxy-5-aza-cytidine (DAC)
demonstrates that hypermethylation occurred in the CP-r cells. The uptake of [
14C]carboplatin, [
3H]FA, and [
3H]MTX increased in an
early stage CP-r cell line (KB-CP1) after treatment with DAC. Both a defective endocytic pathway and DNA hypermethylation
resulting in the downregulation of small regulatory GTPases and cell surface receptors contribute to the reduced accumulation of a
broad range of compounds in CP-r cells.
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Cisplatin (cis-diamminedichloroplatinum II) has become a major
chemotherapeutic agent for treatment of a wide spectrum of solid
tumours. Biochemical, cellular, and molecular approaches have
been used to identify the molecular basis of resistance to cisplatin.
Development of resistance to cisplatin in vivo and in cell lines is
multifactorial, including changes in DNA repair proficiency (Fink
et al, 1998; Branch et al, 2000; Fojo, 2001), proteins and enzymes
involved in detoxicifications of cisplatin, such as metallothionein
and glutathione-related enzymes (Kelly et al, 1988; Godwin et al,
1992; Daubeuf et al, 2002), chaperones (Yamamoto et al, 2001),
signal transduction pathways (Basu et al, 1996), and cell cycle
regulators (Kondo et al, 2001). Alterations in the expression of
proto-oncogenes, apoptosis-related genes, and cancer susceptibil-
ity genes have also been described in association with cisplatin
resistance (Lowe et al, 1993; Husain et al, 1998; Slupianek et al,
2001). Recently, molecular approaches using cDNA microarrays
and differential display have provided useful tools for further
understanding of the molecular mechanisms that contribute to
cisplatin resistance (Grottke et al, 2000; Niedner et al, 2001).
The reduced accumulation of cisplatin is the most consistent
feature seen in cisplatin-resistant (CP-r) cells (Loh et al, 1992;
Johnson et al, 1996; Shen et al, 2000). Mechanisms for drug
resistance resulting from the reduced accumulation of drugs have
been categorised as decreased influx (impaired uptake) and increased
efflux (active export) (Gottesman et al, 2002). We have previously
reported that a pleiotropic defect resulting in the reduced accumula-
tion of [
3H]MTX,
73As
5þ,a n d
73As
5þ in the CP-r cells was found to
be associated with reduced expression of folate-binding protein
(FBP) and arsenic-binding proteins (Shen et al, 1998). The reduced
accumulation of [
14C]carboplatin in CP-r cells in association with
crossresistance to this compound was also documented to be due to a
defect in energy-dependent uptake and not due to active efflux (Shen
et al, 2000). However, the cell biology and molecular bases of the
reduced accumulation in CP-r cells need to be further elucidated.
A defect in fluid-phase endocytosis was found in higher level
CP-r cell lines isolated in multiple steps (Chauhan et al, 2003). To
investigate the cellular and molecular genetic events involved in
cisplatin resistance, particularly for the reduced uptake of a variety
of compounds, reduced expression of several small GTPases
involved in the endocytic pathway and FBP was found in the CP-r
cells as detected by confocal immunofluorescence microscopy,
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yimmunoblotting, and realtime (RT)-PCR. Reactivation of the
silenced FBP gene in the CP-r cells by a demethylation agent, 2-
deoxy, 5-aza-cytidine (DAC), indicated that hypermethylation of
the gene occurred during the development of cisplatin resistance,
and that the uptake defect could be reversed to some extent by
DAC. The data presented here provide evidence that CP-r cells
have a global defect in the uptake of cisplatin and several other
related and unrelated compounds at least related in part to
reduced expression of small GTPases that regulate in endocytic
pathways and DNA hypermethylation in the CP-r cells may play a
role in this pleiotropic phenotype.
MATERIALS AND METHODS
Cell lines and cell culture
Two populations of CP-r cell lines and their parental cell lines were
studied: the human epidermoid carcinoma cell line KB-3-1 and its
CP-r derivative, KB-CP20, and the human liver carcinoma cell line
BEL-7404 and its CP-r derivative, 7404-CP20.
Both human CP-r cell lines were selected in 20mg cisplatinml
 1
medium as described previously (Shen et al, 1998). The early-stage
CP-r cell line KB-CP1 was isolated from the KB-3-1 cells in a two-
step selection including 0.3 and 1mgml
 1 cisplatin (Liang et al,
2003). Figure 1 shows a flow diagram of the derivation of CP-r cell
lines isolated from KB-3-1 and BEL-7404 cells that were used in
this study. All cell lines were grown as monolayer cultures at 371C
in 5% CO2, using Dulbecco’s modified Eagle’s medium with
4.5gl
 1 glucose (Invitrogen, Grand Island, NY, USA), supplemen-
ted with L-glutamine, penicillin, streptomycin, and 10% foetal
bovine serum (BioWhittaker, Walkersville, MD, USA).
Drugs and radiochemicals
All chemicals were purchased from Sigma (St Louis, MO, USA)
unless otherwise noted. Radioactive labelled compounds, such as
[
14C]carboplatin, [
3H]MTX, [
3H]folic acid (FA), [
125I]epidermal
growth factor (EGF), and
59Fe, were purchased from Amersham
Biosciences (Piscataway, NJ, USA). Arsenic-73 at specific activity
242Cimmol
 1 was provided by the Los Alamos National
Laboratory.
73As
5þ was prepared by the reduction of
73As
5þ
50ml of reduction solution consisting of 0.1mM NaAsO2, 66mM
Na2S2O5,2 7m M Na2S2O3, and 82mM H2SO4 was added to 50mlo f
50mCi of
73As
5þ (H3
73AsO4) and incubated for 40min at room
temperature according to Reay and Asher (1997).
Measurement of the accumulation of radiochemicals
Dishes containing a subconfluent monolayer of cells were used for
the assay. For the uptake analysis of [
3H]FA and [
3H]MTX, cells
were washed once with FA-deficient DMEM (Invitrogen), then
incubated at 371C with the same medium containing 0.5mCiml
 1
of radioactive materials. For all other radioactive compounds, cells
were incubated with the regular medium containing 0.5mCiml
 1 of
radioactive materials. After a 1- or 2-h incubation, uptake was
stopped by washing the dishes three times with ice-cold
phosphate-buffered saline, then harvesting cells by trypsinisation.
The cell suspensions were transferred from the dishes into
counting vials with cocktail Ecoscint A (National Diagnostics,
Atlanta, GA, USA) and counted in a Beckman LS3801 liquid
scintillation counter. The radioactivity of the cisplatin-sensitive
(CP-s) parental KB-3-1 cells incubated with various radioactive
compounds was calculated as 100% accumulation, in comparison
to the KB-CP20 cells. Duplicate dishes of cells for each
determination were analysed.
Preparation of enriched plasma membrane proteins
Membrane proteins were purified according to the method of
Cornwell et al (1987). Briefly, 1 10
9 cells from each cell line were
disrupted on ice by nitrogen cavitation with constant stirring for
40min. Two cycles of sucrose gradient ultracentrifugation were
followed. The purified membrane pellets were resuspended in 3ml
TSNa buffer (10mM Tris-HCl pH 7.45, 250mM sucrose, 50mM
NaCl, and 1% aprotinin) and stored at  801C until use.
Immunoblotting
Sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) immunoblotting was carried out as described
previously (Shen et al, 1998). Minigels were run as recommended
by the manufacturer (Invitrogen). Following electrophoresis, the
gels were transblotted onto nitrocellulose membranes (Schleicher
& Schuell, Keene, NH, USA) at 41C. Immunoreaction was
performed with desired primary antibodies and secondary HRP-
conjugated antibodies. Pierce ECL reagents (Pierce Biotechnology,
Rockford, IL, USA) were used for developing signals as described
by the manufacturer. Specific first antibodies and HRP-labelled
secondary antibodies were purchased from BD Biosciences (San
Diego, CA, USA) and Jackson Immuno-Research Lab (West Grove,
PA, USA), respectively, except as indicated.
Confocal image analysis
Cells were cultured in a Lab-Tek Chamber Slide (Nalge Nunc
International, Naperville, IL, USA) and fixed with 70% ETOH at
 201C for 15min. The fixed cells were reacted with the primary
antibodies and then followed by rhodamine-labelled anti-mouse
IgG second antibody. FBP-specific monoclonal antibody MOv19
was a gift from MI Colnagh (Mantovani et al, 1994). Immuno-
fluorescent images of cells were monitored under a laser scanning
confocal microscope (Bio-Rad) at  600 magnification.
RT-PCR
RNA was extracted by Qiagen RNeasy kits as described by the
manufacturer (Qiagen, Valencia, CA, USA). RT-PCR on the
LightCycler instrument (Roche Diagnostics, Indianapolis, IN,
USA) was performed in a total volume of 20ml in the presence
of 2ml of RNA (0.5mg) or water as control. The resolution solution
(Roche, STBR Green I kit) was applied with 2ml per reaction for a
better resolution of melting curves and a significant increase in
sensitivity as for GC-rich templates. Specific primers for desired
genes were added to a final concentration of 10pmol of each
KB-3-1
Cisplatin 500 g ml–1
KB-CP.5
KB-CP1
KB-CP20
(cells growing in cisplatin 0.5 g ml–1)
(cells growing in cisplatin 20 g ml–1)
(cells growing in cisplatin 1 g ml–1)
Mutagenised with
200 g ml–1 EMS 
BEL-7404
7404-CP20
Cisplatin 1 g ml–1
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Figure 1 A flow diagram showing the derivation of CP-r cell lines
isolated from two-step and multistep selection with cisplatin from KB-3-1
(human epidermoid carcinoma cells) and BEL-7404 (human liver carcinoma
cells).
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yoligonucleotide primer. Quantitative analysis of the cDNA
products was determined by the crossing point after 35 cycles of
amplification. A DNA agarose gel was performed to check the size
of the cDNA products and the intensity of fluorescence.
RESULTS
Reduced accumulation of radioactive compounds
In our previous reports, decreased accumulation of [
14C]carbo-
platin, [
3H]MTX,
73As
3þ, and
73As
5þ was found in the CP-r cells.
In this report, we demonstrate that the KB-CP20 cells have a more
global defect in the uptake of a variety of radioactively labelled
compounds. As shown in Figure 2, the accumulation of
[
14C]carboplatin, [
3H]MTX, and [
3H]FA (FA) was decreased over
90% in the CP-r cells compared with the CP-s cells. The decreased
accumulation of [
3H]glucose and [
3H]proline was detected in the
CP-r cells. The uptake of
73As
3þ,
73As
5þ,
59Fe, and [
125I]EGF was
also decreased from 52% to over 80% in the CP-r cells as compared
to CP-s cells. The reduced accumulation of [
125I]EGF is correlated
with decreased expression of the epidermal growth factor receptor
(EGF-R) in our CP-r cells as described previously (Chauhan et al,
2003).
Reduced expression of small GTPases
We have found that KB-CP20 cells have a defect in nonreceptor-
mediated endocytosis (Chauhan et al, 2003) and wondered if this
endocytosis defect in CP-r cells might account for some of the
reduced uptake of nutrients and cytotoxic compounds in CP-r
cells. To explore the endocytosis pathway further, we checked
whether small GTPases and other related proteins known to
regulate endocytosis might also be affected. By immunoblotting
analysis on small GTPases, the expression levels of rab5 and rac1
were noticeably decreased, while rhoA was almost undetectable in
both KB-CP20 and 7404-CP20 cells in comparison to their parental
CP-s cell lines (Figure 3). Quantitative RT-PCR analysis of mRNA
for these small GTPases showed only modest decreases in mRNA
levels (Table 1), indicating that post-transcriptional regulation
might also be involved in the reduction in protein levels. The
expression levels of EEA1, an early endosome marker, and a
clathrin-heavy chain that is involved in receptor-mediated
endocytosis, were similar in these two pairs of human CP-r and
CP-s cell lines, indicating that the reduced accumulation of a
variety of radioactive compounds is not associated with changes of
these two intracellular components. Expression of caveolin was
increased significantly in both KB-CP20 and 7404-CP20 (data not
shown).
Reactivation of silenced FBP genes by a DNA methylation
inhibitor
Since mRNAs encoding many different proteins were reduced in
amount in CP-r cells, we sought to determine whether DNA
hypermethylation might account for decreased transcription of
certain genes in CP-r cells. In our previous paper, we reported that
FBP and its mRNA were almost absent in the CP-r cells by
Northern and immunoblot analysis (Shen et al, 1998). To study
further the mechanism by which the FBP gene was downregulated,
DAC, a DNA demethylation agent, was used to determine whether
the silenced FBP gene could be reactivated as would be expected if
the reduced expression of FBP in CP-r cells were due to
hypermethylation of the gene. The expression levels of the FBP
gene in CP-r cells were significantly elevated after exposure to DAC
at 10mM for 3 days (Figure 4A, upper panel). There were no
changes in CP-s cells after treatment with DAC (data not shown),
indicating that DAC has a specific effect on the activation of
silenced FBP gene in CP-r cells.
There are at least three genes that are known to be commonly
involved in MTX resistance: FBP, reduced folate carrier (RFC), and
dehydrofolate reductase (DHFR) (Hsueh and Dolnick, 1994;
Kelland et al, 1995; Moscow et al, 1995). Figure 4A shows clearly
that only the FBP gene was silenced in the KB-CP20 cells, whereas
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Figure 2 Uptake assay for various radioactively labelled compounds in
KB-CP20 cells in comparison to parental CP-s KB-3-1 cells. The
accumulation rate in the CP-s was taken as 100%. Cell lines used are
described in Figure 1. Cells were incubated with the indicated radioactive
compound at 371C for 1h. Measurement of radioactivity in cells is
described in Materials and methods.
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Figure 3 Protein profiles by immunoblot analysis as visualised by ECL.
Enriched plasma membranes were transblotted onto nitrocellulose
membranes after 10% SDS–PAGE as described in Materials and methods.
Cells lines used in this analysis are described in Figure 1.
Table 1 Reduced expression of several small GTPases and cell surface
proteins in CP-r cells, measured by RT-PCR
a
Levels of expression
a
Genes KB-3-1 KB-CP20
rab5 1 0.8
rac1 1 0.5
rhoA 1 0.4
FBP 1 o0.0015
RFC 1 0.6
DHFR 1 0.63
RT-PCR¼real-time PCR; FBP¼folate-binding protein; RFC¼reduced folate carrier;
DHFR¼dehydrofolate reductase.
aLevels of gene expression are based on the
differences in crossing points, which represents the number of gene duplication cycles
as determined by a LightCycler RT-PCR.
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ychanges in the expression of RFC and DHFR genes were
undetectable. After treatment with DAC, expression levels of the
FBP gene were elevated as the concentrations of DAC increased.
There was no effect on the expression of RFC and DHFR by DAC
treatment. These results demonstrate that the FBP gene was
specifically downregulated during the acquisition of cisplatin
resistance and could be reactivated by demethylation of the gene
with DAC.
How persistent was DAC-activated gene expression? Figure 4B
demonstrates that the expression of the FBP gene induced by DAC
persisted for at least 12 days after initial exposure to the
methylation inhibitor for 4 days. The induced expression levels
of the FBP gene were quite similar among the CP-r cells treated
with DAC at 0.3mM for 12 days, or 10mM for 4 days, or 1mM for 4
days followed by DAC-free medium for 12 days.
Increased uptake of
14C-carboplatin, [
3H]FA and [
3H]MTX
induced by DAC
Since reduced expression of the FBP gene in CP-r cells could be
reactivated by DAC as seen in Figure 3A, we asked whether
induced gene expression in CP-r cells would result in increasing
the uptake of compounds whose uptake was reduced in the
resistant cells. Uptake assays were performed using radioactively
labelled compounds, [
14C]carboplatin, [
3H]FA, and [
3H]MTX.
Cells were treated with DAC, 1mM for KB-3-1 and KB-CP1 cells,
and 5mM for KB-CP20 cells at 371C for 3 days, then reincubated
with DAC-free medium for another 3 days for recovery. After
incubation with the desired radioactively labelled compounds at
371C for 2h, increased accumulation of [
14C]carboplatin could be
seen in DAC-treated two-step selected KB-CP1 cells only
(Figure 5A). There was little effect of DAC on the parental KB-3-
1 cell line or on the KB-CP20 cell line. The uptake of [
3H]FA and
[
3H]MTX could be stimulated up to 687 and 398%, respectively, in
DAC-treated KB-CP1 cells compared to untreated cells (Figure 5B
and C). For FA and methotrexate uptake, DAC also had less than a
two-fold effect on the parental KB-3-1 cells. However, the KB-CP20
cells were nonresponsive to DAC treatment in the accumulation of
[
3H]FA. In parallel with the increased uptake of the above
radioactively labelled compounds, the expression of the FBP gene
in KB-CP1 cells was also increased after treatment with DAC for 3
days and then 3 days in DAC-free medium as detected by RT-PCR
(Figure 6A). Immunostaining with a monoclonal antibody specific
to FBP detected by confocal microscopy indicated that the
intensity of the fluorescence was increased in both DAC-treated
KB-CP1 and KB-CP20 cells in comparison with their untreated
control cells (Figure 6B). FBP was largely localised at the cell
surface in the KB-CP1 cells after DAC activation, while the protein
was mostly found in a Golgi-like distribution inside the cell in the
KB-CP20 cells treated with DAC, explaining why this increased
expression did not result in increased uptake of methotrexate and
FA.
DISCUSSION
In this work, we have examined the cellular and molecular basis of
an extremely pleiotropic phenotype of CP-r cells that creates global
alterations in gene expression resulting in altered expression of cell
surface protein and decreased endocytosis. These changes have the
net effect of decreased accumulation of cisplatin and many other
compounds. Unlike other forms of multidrug resistance due to
energy-dependent efflux pumps, such as MDR1, MXR (ABCG2),
and MRP family members (Borst and Elferink, 2002; Gottesman
et al, 2002), this form of multidrug resistance causes decreased
drug accumulation by blocking normal modes by which agents
such as cisplatin enter cells. In this work, we show an association
between the reduced uptake of a variety of cisplatin-related or -
unrelated radioactive compounds and a defective endocytic
FBP
RFC
DHFR
DAC M  0           0          1     5
KB-3-1 KB-CP20
A
KB-3-1 KB-CP20
DAC M  0    0    0.3 0   1     0   10
× Days  12 16 4    12 4
FBP
B
Figure 4 Reverse transcriptase PCR analysis on gene expression. (A)
FBP, RFC, and DHFR genes. (B) Duration of activation of FBP gene by
DAC, and the concentrations and time periods of DAC treatment were
marked in the figure. RNA preparation and RT-PCR were performed as
described in Materials and methods. KB-3-1 and KB-CP20 cells were
described in Figure 1.
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Figure 5 Uptake assay for radioactively labelled compounds in the CP-s
and CP-r cells after treatment with DAC. Cells were incubated with the
desired radioactive compound at 371C for 2h. (A)[
14C]carboplatin, (B)
[
3H]FA, and (C)[
3H]MTX. KB-3-1 and KB-CP20 cells were described in
Figure 1.
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inhibitor DAC.
Recently, decreased intracellular accumulation of cisplatin, one
of the most important characteristics of CP-r cells, has attracted
investigators’ interest. The mechanism(s) by which cisplatin enters
the cell and how decreased accumulation occurs in resistant cells
are still not defined. Generally, the pathways by which cisplatin
and its analogs are thought to enter the cell can be subdivided into
three categories: passive diffusion, carrier or receptor-mediated
transport, and entry via ion channels (Gottesman et al, 2002). Our
previous data demonstrated that [
14C]carboplatin enters cells via
an energy-dependent transport process (Shen et al, 2000), and the
reduced accumulation of [
14C]carboplatin was due to impaired
influx and not due to active efflux. It has been found recently in
our laboratory that cisplatin resistance is associated with a defect
in endocytosis and changes in lysosomal acidification (Chauhan
et al, 2003), with mislocalisation of transporters and carriers, such
as MRP1 and FBP (Liang et al, 2003).
In this study, we sought to understand the molecular and
biochemical basis of the defective endocytosis in the CP-r cells.
The expression of small GTPases, such as rab5, rac1, and rhoA,
which are regulators of the endocytosis machinery (Ellis and
Mellor, 2000; Sonnichsen et al, 2000; Sorkin, 2000), was down-
regulated in the CP-r cells. However, clathrin, and the early
endosomal marker EEA1, remained unchanged in the CP-r cells
(Figure 3).
The above results indicate that impaired uptake of cisplatin,
[
14C]carboplatin, [
3H]MTX, and other compounds in CP-r cells
was associated with the downregulation of several small GTPases
involved in regulating the endocytosis machinery, possibly also
resulting in mislocalisation of transporters, receptors/carriers,
such as FBP, EGFR, and TFR. The reduced uptake of dextran-10
and horseradish peroxidase, which are fluid-phase endocytosis
markers, was observed in CP-r cells (Chauhan et al, 2003). Clathrin
levels were relatively unaffected in our CP-r cells, indicating that
the defective endocytic pathway in CP-r cells is clathrin
independent. Although a decline in protein levels was not always
directly correlated with reduced mRNA levels (Table 1 vs Figure 3),
suggesting post-transcriptional regulation in some cases, reduced
protein was always associated with some reduced mRNA.
The data presented in this work raise the question as to whether
reduced transcription could account for the reduced expression of
transporters, receptors, carriers, and small GTPases in the CP-r
cells. DNA hypermethylation has been reported in multidrug-
resistant cell lines, including CP-r cells (Plumb et al, 2000; Efferth
et al, 2001; Borst and Elferink, 2002). A link between mismatch
repair deficiency and cytotoxic drug resistance was ascribed to
hypermethylation of the promoter regions of genes involved in
DNA repair (Strathdee et al, 1999).
In our work, the FBP gene was chosen as a model because of its
association with reduced uptake and crossresistance to MTX in
CP-r cells. Preliminary results have shown differences in methyla-
tion patterns of the FBP gene in parental and CP-r cells (data not
shown). To study the relation between the downregulation of gene
expression and DNA hypermethylation, DAC, a demethylating
agent, was applied to see if the silenced FBP gene and other genes
could be reactivated. DAC has been shown to replace cytidine
residues in replicating DNA and prevent methylation, thereby
demethylating or inducing hypomethylation of DNA (Hsueh and
Dolnick, 1994). It is evident from this work that the silenced FBP
gene in KB-CP20 cells could be reactivated by DAC (Figure 4). The
duration of reexpression of the FBP gene was at least 12 days after
initial exposure to this compound for 4 days.
FBP, as mentioned above, and RFC are both involved in the
uptake of MTX, while DHFR is a cytotoxic target for MTX. The
data reported here indicate that only FBP expression was
remarkably reduced and that there was little change in the
expression of RFC and DHFR genes in the CP-r cells (Figure 4A).
No response of the RFC gene to DAC treatment was observed,
whereas the expression of DHFR was elevated about 2–3-fold after
DAC induction.
Uptake assays on [
14C]carboplatin, [
3H]FA, and [
3H]MTX in
DAC-treated or -untreated cells revealed that DAC treatment
increased the accumulation of these compounds in KB-CP1 cells.
The parental KB-3-1 cells had no response to DAC for uptake of
[
14C]carboplatin with some increase in the uptake of [
3H]FA and
[
3H]MTX. In contrast, DAC showed little effect on uptake in the
high-level Cp-r KB-CP20 cells. Why did expression of the FBP
gene in the KB-CP20 cells after treatment with DAC not result in
increased uptake of [
3H]FA and [
3H]MTX? Confocal microscopic
images revealed that expression of the FBP gene was elevated
in the KB-CP20 cells, but FBP was not localised at the cell
surface. Instead, it was distributed in the cytoplasm. Therefore, it
could not function as a cell surface carrier for MTX. In the KB-CP1
cells, FBP induced by DAC was largely localised at the cell surface,
explaining the increased uptake of MTX and FA under these
conditions.
Taken together, these data suggest the existence of a novel
cellular defense system or systems that result in cisplatin resistance
and crossresistance to other related and unrelated drugs. Defects in
this system, which cause decreased uptake of many compounds,
lead to reduced expression and mislocalisation of certain genes,
such as transporters, that is, MRP1 (Liang et al, 2003) and MRP2-4
(data not shown), carriers, that is, FBP, and genes involved in
endocytic pathways and protein trafficking, that is, some small
GTPases. In this work, we show that the FBP gene was turned down
or off by DNA hypermethylation triggered by selection in cisplatin.
Whether DNA methylation is a primary or secondary event is not
clear, but demethylation by DAC results in at least partial re-
expression and function of some of the gene products. These
findings may provide valuable information for the design of
0     0      1      3      5
FBP
B
KB-CP1 KB-CP1
KB-CP20 KB-CP20
A
DAC M
KB-3-1 KB-CP1
–DAC +  DAC
KB-CP20
Figure 6 (A) Reverse transcriptase PCR analysis of DAC activation on
KB-CP1 cells. The cell lines used in this study were described in Figure 1.
Measurement of radioactivity in cells is described in Materials and methods.
(B) Confocal microscopic immunofluorescent images of FBP stained by a
monoclonal antibody specific to human FBP. Immunofluorescent images of
cells were monitored under a laser scanning confocal microscope (Bio-Rad)
at  600 magnification.
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to detect drug resistance before and after chemotherapy with
cisplatin by monitoring changes of DNA methylation status and
expression levels of small GTPases and FBP in clinical tumour
specimens.
In an effort to see if cisplatin resistance is related to the
overexpression of the copper transporter, we inserted the
human copper transporter hCTR1 (Zhou and Gitschier, 1997)
into the expression vector pcDNA3.1, then transfected this into
CP-s cells. Figure 7 shows killing curves indicating little difference
in cells transfected with the control mock vector and two
individual hCTR1 expression vectors in levels of resistance to
cisplatin.
Recent data from Howell’s lab demonstrated that two P-type of
ATPases ATP7A and ATP7B are involved in cisplatin resistance in
human ovarian carcinoma cells by modulating cellular pharmacol-
ogy of cisplatin and other metals, suggesting that a sequestration
and secretory system may exist (Katano et al, 2002, 2003).
Therefore, it is possible that there might be at least two pathways
for the reduced accumulation of cisplatin and other related
chemicals in CP-r cells: impaired uptake and active secretion.
These results will help us to understand the multifactorial
mechanisms in acquisition and development of cisplatin resistance
in human cancer cells.
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